Transcatheter heart valve implantation is a minimally-invasive heart procedure to repair damaged heart valves with bio-prosthetic valves for treatment of valvular heart disease (VHD). It is an alternative approach to conventional open heart surgery and is especially recommended for extremely high risk patients. The aortic valve is located between the left lower heart chamber (left ventricle) and the body's main artery (aorta). If the valve does not open correctly, blood flow from the heart to the body is reduced. Transcatheter aortic valve replacement (TAVR) is approved by the U.S. FDA for treating individuals suffering from symptomatic aortic stenosis and are at high risk for standard valve replacement surgery. TAVR can help restore blood flow and reduce the signs and symptoms of aortic valve stenosis — such as chest pain, shortness of breath, fainting and fatigue. TAVR may be an option for people who are at risk of complications from surgical aortic valve replacement (open-heart surgery). Increasing demand for minimally-invasive procedures is expected to boost growth of the global transcatheter heart valve market over the forecast period.
Market Dynamics
Increasing adoption of inorganic growth strategies, such as acquisitions by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in June 2020, SMT, a manufacturer of medical equipment, announced that it has acquired structural heart medical device firm Vascular Concepts, to enter into the market.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook